The Dermatology Clinical Trials Unit is nationally recognized for developing and participating in clinical therapeutic trials. Clinical trials allow our patients to be exposed to experimental therapeutics. The trials unit is experienced in all areas of dermatologic clinical research from pre-Phase I to Phase IV. We are currently participating in a broad range of clinical trials of novel therapeutics for inflammatory and neoplastic skin disorders. The trials unit draws on the Division of Dermatology’s vast clinical experience.

Dermatology Clinical Trials Unit

Stephanie Farris, Clinical Research Coordinator, Main Campus
Phone: 314-747-8694 Fax: 314-362-6080

Andrea Kuehn, Clinical Research Coordinator, West County
Phone: 314-996-3429

Justin Stout, Clinical Research Coordinator, Main Campus
Phone: 314-273-3737 Fax: 314-362-6080

Mary Tabacchi, CRCC, Sr. Clinical Research Coordinator, All sites
Phone: 314-362-8171 Fax: 314-362-6080

Milan Anadkat, MD, Director, Clinical Trials Unit 

Currently Enrolling Trials

Dr. Milan Anadkat- (COH)

A Phase II Study to Evaluate the Safety and Efficacy of OQL011 (topical nitroglycerin) on VEGFR Inhibitor-Associated Hand-foot Skin Reaction in Cancer Patients

A Phase II, Randomized, Placebo-controlled, Double-blind, Multiple Dose Study to Evaluate the Efficacy and Safety of ANB019 (IL-36R antagonist) in Subjects with Palmoplantar Pustulosis

A study to test whether BI 655130 (Spesolimab-IL-36) prevents flare-ups in patients with Generalized Pustular Psoriasis

A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab (IL-1; SQ) in Subjects with Moderate to Severe Hidradenitis Suppurativa

A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib (JAKi) (Oral) in Adult Subjects with Moderate to Severe Hidradenitis Suppurativa

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of LY3041658 (CXCR1, 2) (Intravenous) in Adults with Moderate to Severe Hidradenitis Suppurativa

A pragmatic study of home versus office-based narrow band ultraviolet B phototherapy for the treatment of psoriasis (Short Title: Light Treatment Effectiveness (LITE) Study)

Dr. Heather Jones- (COH)

Clinical Study for Pediatric Patients (age 6-17) with Psoriasis to assess the efficacy, safety, and pharmacokinetics of Certolizumab Pegol (TNF antagonist)

Pivotal Phase III study: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects with Prurigo Nodularis

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group study to Evaluate the Efficacy and Safety of Dupilumab in Patients with Prurigo Nodularis who are Inadequately Controlled on Topical Prescription Therapies or when those Therapies are Not Advisable

Dr. Ann Martin- (West County)

Randomized, Double-Blind, Vehicle-Controlled, Multicenter Study to Assess the Efficacy and Safety of Methyl aminolevulinate hydrochloride (MAL) 16.8% cream (CD06809-41) versus vehicle cream in the treatment of thin and moderately thick, non-hyperkeratotic, non-pigmented actinic keratosis of the face and scalp when using daylight photodynamic therapy (DL-PDT)

A Phase 3, Double-Blind, Randomized, Vehicle Controlled, Efficacy and Safety Study of Ruxolitinib Cream followed by an Extension Period in Participants with Vitiligo

Dr. Amy Musiek- (COH)

SOLAR: A Phase 2, Randomized, Open-label, Parallel-group, Active Comparator, Multi-center Study to Investigate the Efficacy and Safety of Cobomarsen (MRG-106) in Subjects with Cutaneous T-Cell Lymphoma (CTCL), Mycosis Fungoides (MF) Subtype

Phase 2A, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of PF-06823859 (IFN antagonist) in Adult Subjects with Dermatomyositis

A Double Blind, Randomized, Vehicle Controlled, Crossover Study to Evaluate the Safety and Efficacy of Topical Naloxone Hydrochloride Lotion 0.5% for the Relief of Pruritus in Patients with the Mycosis Fungoides (MF) or Sézary Syndrome (SS) Forms Form of Cutaneous T-Cell Lymphoma (CTCL)

Evaluation of the Pharmacokinetics and Safety of Upadacitinib (JAK-inhibitor) in Pediatric Subjects (ages 2-11) with Severe Atopic Dermatitis